Nanoporous Immunoprotective Device for Stem-Cell-Derived β-Cell Replacement Therapy.

Area of Science:

• Biomedical Engineering
• Regenerative Medicine
• Immunology

Background:

• Diabetes treatment often requires lifelong immune suppression for cell therapies.
• Human embryonic stem-cell-differentiated beta cell clusters (hES-βC) offer a potential cell source for diabetes therapy.
• Effective immune protection is crucial for the success of transplanted cells.

Purpose of the Study:

• To develop and evaluate a nanoporous immunoprotective polymer thin film device for encapsulating hES-βC.
• To assess the biocompatibility and efficacy of the encapsulation device in vivo.
• To determine if the device can prevent immune rejection and allow long-term cell function.

Main Methods:

• Fabrication of a nanoporous polymer thin film encapsulation device.
• In vitro assessment of oxygen and nutrient exchange and immune molecule exclusion.
• In vivo biocompatibility studies, including neovascularization and foreign body response assessment.
• Evaluation of teratoma containment and long-term engraftment, viability, and function of encapsulated hES-βC in animal models.

Main Results:

• The device successfully excluded immune molecules while allowing essential nutrient and oxygen exchange.
• Biocompatibility studies showed the device promoted neovascularization with a limited foreign body response.
• The device prevented teratoma escape and demonstrated successful immuno-isolation of encapsulated cells.
• Long-term (6-month) animal studies confirmed engraftment, viability, and function of encapsulated hES-βC.

Conclusions:

• Nanoporous polymer thin film encapsulation is a viable strategy for protecting transplanted cells.
• This technology enables immune-isolated cell therapy for diabetes without systemic immunosuppression.
• The developed device supports long-term survival and function of hES-βC, paving the way for potential clinical applications.